Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Thioridazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 6/20 | 0.98 |
| ▸ | DRD3 known ✓ | P35462 | 4/20 | 0.98 |
| ▸ | HTR2A known ✓ | P28223 | 4/20 | 0.98 |
| ▸ | DRD4 known ✓ | P21917 | 1/20 | 0.98 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.98 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | STAT6 | P42226 | 1/20 | 1.00 |
| ▸ | RAD52 | P43351 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thioridazine SCHEMBL41430 | 1.00 | TDP1 (1.00) | TDP1MAPTALDH1A1TP53CYP3A4 | |
| Thioridazine SCHEMBL30827481 | 1.00 | TDP1 (1.00) | TDP1MAPTALDH1A1TP53CYP3A4 | |
| Thioridazine SCHEMBL8006297 | 1.00 | TDP1 (1.00) | TDP1MAPTALDH1A1TP53CYP3A4 | |
| Thioridazine SCHEMBL380206 | 0.99 | PIM1 (1.00) | TDP1MAPTALDH1A1TP53CYP3A4 | |
| Thioridazine SCHEMBL9566 | 0.99 | PIM1 (1.00) | TDP1MAPTALDH1A1TP53CYP3A4 | |
| Thioridazine SCHEMBL29384252 | 0.99 | PIM1 (1.00) | TDP1MAPTALDH1A1TP53CYP3A4 | |
| Thioridazine SCHEMBL2577719 | 0.99 | PIM1 (1.00) | TDP1MAPTALDH1A1TP53CYP3A4 | |
| Thioridazine SCHEMBL12434241 | 0.99 | PIM1 (1.00) | TDP1MAPTALDH1A1TP53CYP3A4 | |
| Thioridazine SCHEMBL56533 | 0.97 | PIM1 (0.96) | TDP1MAPTALDH1A1TP53CYP3A4 | |
| Thioridazine SCHEMBL2321422 | 0.93 | TDP1 (0.87) | TDP1MAPTALDH1A1TP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| WO-2024102612-A1 | COMPOUNDS AND METHODS FOR IDENTIFYING COMPOUNDS FOR MODULATING GLUCOSE TRANSPORT | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-05-16 | — | — | WO | claimed |
| CN-114191553-A | Medicine for resisting novel coronavirus SARS-CoV-2 and its application | 中国医学科学院病原生物学研究所 | 2022-03-18 | — | — | CN | claimed |
| CN-114191552-A | Medicine for resisting novel coronavirus SARS-CoV-2 and its application | 中国医学科学院病原生物学研究所 | 2022-03-18 | — | — | CN | claimed |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| EP-3749325-B1 | DREADD ACTUATORS | US HEALTH (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260027215-A1 | COMPOSITIONS FOR TRANSPORT OF THERAPEUTIC CARGOS USING BINDERS TARGETING CA-IV | RECEPTIVE BIO INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-20250381149-A1 | CATIONIC AMPHIPHILIC COMPOUND-BASED NANOPARTICLE COMPOSITIONS | UNIVERSITEIT GENT (BE) | 2025-12-18 | — | — | US | disclosed |
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | Didenko, Kirill (US) | 2025-07-03 | — | — | US | disclosed |
| WO-2025119299-A1 | METHOD FOR DIFFERENTIATING PANCREATIC BETA CELLS | HANGZHOU REPROGENIX BIOSCIENCE, INC. (CN) | 2025-06-12 | — | — | WO | disclosed |
| WO-2025041882-A1 | BIOMARKER FOR EVALUATING DRUG TOXICITY OF LIVER ORGANOID | 한국표준과학연구원 | 2025-02-27 | — | — | WO | disclosed |
| US-20250057819-A1 | DRUG COMBINATIONS FOR INHIBITING CORONAVIRUS REPLICATION | INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CA) | 2025-02-20 | — | — | US | disclosed |
| US-20220313656-A1 | NEW CLASS OF ANTIBIOTICS HAVING LOW MIC-VALUES TOWARDS DIFFERENT STRAINS OF BACTERIA | Københavns Universitet (DK) | 2022-10-06 | — | — | US | disclosed |
| US-11446353-B2 | Compositions and methods for the treatment of fungal infections | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2022-09-20 | — | — | US | disclosed |
| US-20220175714-A1 | USE OF RIVASTIGMINE IN PREPARATION OF ANTI-RADIATION MEDICAMENT | SOOCHOW UNIVERSITY (CN) | 2022-06-09 | — | — | US | disclosed |
| CN-113564122-B | Method for differentiating human induced pluripotent stem cells into oligodendrocytes, kit and application | 呈诺再生医学科技(珠海横琴新区)有限公司 | 2022-04-08 | — | — | CN | disclosed |
| CN-114191553-A | Medicine for resisting novel coronavirus SARS-CoV-2 and its application | 中国医学科学院病原生物学研究所 | 2022-03-18 | — | — | CN | disclosed |
| CN-114191552-A | Medicine for resisting novel coronavirus SARS-CoV-2 and its application | 中国医学科学院病原生物学研究所 | 2022-03-18 | — | — | CN | disclosed |
| EP-3958975-A1 | NEW CLASS OF ANTIBIOTICS HAVING LOW MIC-VALUES TOWARDS DIFFERENT STRAINS OF BACTERIA | Københavns Universitet (DK) | 2022-03-02 | — | — | EP | disclosed |
| US-11246873-B2 | Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220313656-A1 | NEW CLASS OF ANTIBIOTICS HAVING LOW MIC-VALUES TOWARDS DIFFERENT STRAINS OF BACTERIA | NR4A1, NR4A3, NR1H4 | DRD2 136/4885DRD3 33/4885HTR2A 1220/4885 |
| US-20250381149-A1 | CATIONIC AMPHIPHILIC COMPOUND-BASED NANOPARTICLE COMPOSITIONS | NPC1L1, NPC1, ABCB4 | DRD2 4816/4885DRD3 4767/4885HTR2A 4186/4885 |
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | ACE2, FURIN, SARS1 | DRD2 4342/4885DRD3 4575/4885HTR2A 1457/4885 |
| US-20260027215-A1 | COMPOSITIONS FOR TRANSPORT OF THERAPEUTIC CARGOS USING BINDERS TARGETING CA-IV | CA4, FLT4, CAMK4 | DRD2 3656/4885DRD3 3317/4885HTR2A 965/4885 |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | DRD2 4171/4885DRD3 3787/4885HTR2A 1608/4885 |
| US-20250057819-A1 | DRUG COMBINATIONS FOR INHIBITING CORONAVIRUS REPLICATION | MME, ACE, ACE2 | DRD2 100/4885DRD3 102/4885HTR2A 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.